

Special Issue

Systemic Lupus Erythematosus: From Molecular Mechanisms to Therapies

Message from the Guest Editor

Systemic lupus erythematosus is a second after rheumatoid arthritis systemic rheumatic disease, with different organ and system involvement with different courses. Systemic lupus erythematosus may affect all ages. Monogenic SLE should be mentioned in early-onset and family cases. The interferon-I signaling pathway and other inherited immune-mediated disturbances are the basis of SLE pathogenesis. The study of molecular and immunology mechanisms is the key to finding new surrogate biomarkers of activity and new targeting treatment options. The research of SLE pathogenesis can improve the patients' quality of life, live expectancy and long-term outcomes. This Special Issue of *Biomedicines* focuses on recent advances in the discovery, characterization, translation, and clinical application of systemic lupus erythematosus and targets. Our goal in publishing this Issue is to stimulate research and clinical interests in this exciting field, with the hope of developing strategies for the diagnosis and assessment of activity and damage, molecular pathogenesis, and improvement of treatment outcomes for patients with systemic lupus erythematosus.

Guest Editor

Prof. Dr. Mikhail Kostik

Department of Hospital Pediatrics, Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia 2, Litovskaya St., Saint Petersburg 194100, Russia

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157393

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).